News | May 27, 2026
Jubilant Ingrevia delivers 14-quarter high revenue in Q4 FY26 as margins strengthen across biz
The company highlighted continued demand strength and pricing resilience despite global disruptions
The company highlighted continued demand strength and pricing resilience despite global disruptions
Revenue from operations climbed 13% to Rs. 886.87 crore
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios
Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26
The company reported free cash flow of Rs. 2,590 Mn for FY26
Subscribe To Our Newsletter & Stay Updated
